PipelineReview.com4h
Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...
Pharma giant partners with Durham firm to target sickle cell disease
IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...
ncbiotech.org1d
IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
Barron's3d
Novo Nordisk A/S ADR
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...